Literature DB >> 22525273

Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide.

K-W Cho1, J H Park, C-W Park, D Lee, E Lee, D J Kim, K J Kim, S H Yoon, Y Park, E Kim, S Cho, S Jang, B-C Park, S-W Chi, S H Yoo, M H Jang, H N Kim, E Kim, K Jo, Y W Park.   

Abstract

Since c-Met has an important role in the development of cancer, it is considered as an attractive target for cancer therapy. Although molecular mechanisms for oncogenic property of c-Met have been actively investigated, regulatory elements for c-Met endocytosis and its effect on c-Met signaling remain unclear. In this study, we identified a pivotal endocytic motif in c-Met and tested it for selective modulation of HGF-induced c-Met response. Using various chimeric constructs with the cytoplasmic tail of c-Met, we were able to demonstrate that a dileucine motif located in the C-terminus of c-Met acts to regulate its endocytosis. Synthetic peptide Ant-3S, consisting of antennapedia-derived protein transduction domain (designated as Ant) and c-Met-derived 16 amino-acids (designated as 3S, spanning amino-acids 1378 to 1393), rapidly moved into cancer cells and disrupted c-Met trafficking. Importantly, an extension of c-Met retention time on the membrane by Ant-3S peptide significantly decreased phosphorylation-dependent c-Met signal transduction. Additionally, the peptide effectively inhibited HGF-induced cell growth, scattering and migration. The underlying molecular mechanism for these observations has been investigated and revealed that the dileucine motif interacts with endocytic machinery, including adaptin β and caveolin-1, for sustained and enhanced signal transduction. Finally, Ant-3S peptide specifically blocked internalization of interleukin-2 receptor α-subunit/3S chimeric protein, but not the other receptors, including Glut4, Glut8 and transferrin receptor. Such results indicate the presence of a selective endocytic assembly for c-Met. It also suggests a potential for c-Met-specific anti-cancer therapy using the identified endocytic motif in this study.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22525273     DOI: 10.1038/onc.2012.122

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  5 in total

1.  MicroRNA-144 inhibits the metastasis of gastric cancer by targeting MET expression.

Authors:  Jun Liu; Hui Xue; Jianjun Zhang; Tao Suo; Yijin Xiang; Wen Zhang; Jun Ma; Dingfang Cai; Xixi Gu
Journal:  J Exp Clin Cancer Res       Date:  2015-04-17

2.  Reciprocal activating crosstalk between c-Met and caveolin 1 promotes invasive phenotype in hepatocellular carcinoma.

Authors:  Peyda Korhan; Esra Erdal; Emine Kandemiş; Murat Cokaklı; Deniz Nart; Funda Yılmaz; Alp Can; Neşe Atabey
Journal:  PLoS One       Date:  2014-08-22       Impact factor: 3.240

3.  HGF-independent regulation of MET and GAB1 by nonreceptor tyrosine kinase FER potentiates metastasis in ovarian cancer.

Authors:  Gaofeng Fan; Siwei Zhang; Yan Gao; Peter A Greer; Nicholas K Tonks
Journal:  Genes Dev       Date:  2016-07-01       Impact factor: 11.361

4.  The Chemokine Receptor CXCR4 and c-MET Cooperatively Promote Epithelial-Mesenchymal Transition in Gastric Cancer Cells.

Authors:  Yu Cheng; Yongxi Song; Jinglei Qu; Xiaofang Che; Na Song; Yibo Fan; Ti Wen; Ling Xu; Jing Gong; Xiaoxun Wang; Chenlu Zhang; Xiujuan Qu; Yunpeng Liu
Journal:  Transl Oncol       Date:  2018-02-27       Impact factor: 4.243

5.  The unfolded protein response modulators GSK2606414 and KIRA6 are potent KIT inhibitors.

Authors:  Mohamed Mahameed; Thomas Wilhelm; Odai Darawshi; Akram Obiedat; Weiss-Sadan Tommy; Chetan Chintha; Thomas Schubert; Afshin Samali; Eric Chevet; Leif A Eriksson; Michael Huber; Boaz Tirosh
Journal:  Cell Death Dis       Date:  2019-04-01       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.